1. Suh JH et al. Comprehensive genomic profiling facilitates implementation of the National Comprehensive Cancer Network Guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials. The Oncologist 2016;21:684–91.
2. Frampton GM et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotech 2013;31(11):1023–33.
3. Ross JS et al. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol 2013;130:554–9.
4. Chalmers ZR et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumour mutational burden. Genome Med 2017;9:34.
5. FoundationOne® Technical Information.
6. FoundationACT® Technical Information.
7. FoundationOne®Heme Technical Information.
8. He J et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood 2016;127(24):3004–14.
9. Stephens PJ et al. Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors. Ann Oncol 2016;27(Suppl 6):vi401–6; Abstract 1159PD.
10. Yelensky R et al. Analytical validation of solid tumor fusion gene detection in a comprehensive NGS-based clinical cancer genomic test. Cancer Res 2014;74(Suppl 19):Abstract 4699
11. Yelensky R et al. Analytical validation of solid tumor fusion gene detection in a comprehensive NGS-based clinical cancer genomic test. 2014. Poster presented at AACR Annual Meeting 2014; April 5–9 2014; San Diego, California, US.
12. FoundationOne® Specimen Guidelines.
13. Drilon A et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in “driver-negative” lung adenocarcinomas. Clin Cancer Res 2015;21(16):3631–9.
14. Rozenblum AB et al. Clinical impact of hybrid capture-based next-generation sequencing on changes in treatment decisions in lung cancer. J Thorac Oncol 2017;12(2):258–68.
15. Frampton GM et al. Assessment and comparison of tumor mutational burden and microsatellite instability status in >40,000 cancer genomes Ann Oncol 2016;27(Suppl 6):Abstract 520.
16. Rizvi NA et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 2015;348(6230):124–8.
17. Rosenberg JE et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.
18. Snyder A et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Eng J Med 2014;371(23):2189–99.
19. National Cancer Institute (NIH). NCI dictionary of cancer terms Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=285933 (accessed February 2017).
20. Dudley JC et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016;22(4):813–20.
21. Diaz LA et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol May 2017:suppl 3071 (10.1200/JCO.2017.35.15_suppl.3071);35(15).
22. Siravegna G et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017;14(9):531–48.
23. Krishnamurthy N et al. Liquid biopsies for cancer: coming to a patient near you. J Clin Med 2017;6:3.
24. Stephens PJ et al. Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors. 2016. Poster 1159PD presented at Annual ESMO Congress, Copenhagen, Denmark, 2016.
25. Young L et al. Kinase fusions in non-small cell lung carcinoma by hybrid-capture-based ctDNA assay. 2016; Poster 7014.
26. Ou S-A I et al. Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET Exon 14 skipping. J Thorac Oncol 2016;12(1):137–40.
27. Allen JM et al. Genomic profiling of circulating tumor DNA in relapsed EGFR-mutated lung adenocarcinoma reveals an acquired FGFR3-TACC3 fusion. Clin Lung Cancer 2016;18(3):e219–22.
28. Dagogo-Jack I et al. Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC). Poster presented at ASCO 2017; Poster 9025.
29. Pusztai L et al. Genomic profiling of circulating tumor DNA (ctDNA) from patients with metastatic breast cancer. Poster presented at ASCO 2017; Poster 1016.
30. Chung JH et al. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Ann Oncol 2017: In press.
31. Schrock AB et al. Genomic profiling of circulating tumor DNA (ctDNA) from patients with advanced cancers of the GI tract and anus. Poster presented at ASCO 2017; Poster 618.
32. Lara PN et al. Comprehensive characterization of BRCA1 and BRCA2 alterations in circulating tumor DNA and tumor tissue in men with prostate cancer: implications for clinical care. Poster presented at ESMO 2017; Poster 827P.
33. Hinrichsen T et al. Detection and characterization of circulating cell free tumor DNA in cancer patients with malignant solid tumors. Liquid biopsy: a new tool in molecular pathology? J Lab Med 2016;40(5):313–22.
34. Wan JCM et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017;17:223–38.
35. Haber DA and Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014;4(6):650–61.
36. Vendrell JA et al. Circulating cell free tumor DNA detection as a routine tool for lung cancer patient management. Int J Mol Sci 2017;18:264.
37. Diehl M et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14(9):985–90.
38. Bettegowda C et al. Detection of circulating tumour DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6(224):224ra24.
39. Diaz LA and Bardelli A. Liquid biopsies: genotyping circulating tumour DNA. J Clin Oncol 2014;32(6):579–86.
40. Leung F et al. Circulating tumor DNA as a cancer biomarker: fact or fiction? Clin Chem 2016;62(8):1054–60.
41. Forte VA et al. The potential for liquid biopsies in the precision medical treatment of breast cancer. Cancer Biol Med 2016;13(1):19–40.
42. Tie J et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 2015;26:1715–22.
43. Data on file. Foundation Medicine TMB and MSI.
44. Hu L et al. Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. Biomarker Research 2014;2:3.
45. Bridge JA. Advantages and limitations of cytogenetic, molecular cytogenetic, and molecular diagnostic testing in mesenchymal neoplasms. J Orthop Sci 2008;13:273–82.
46. Chen AY-Y and Chen A. Fluorescence in situ hybridization. J Invest Dermatol 2013;133:e8.
47. Lin F and Prichard J (eds). Handbook of Practical Immunohistochemistry 2015. Frequently Asked Questions, 2nd edition. Springer Science + Business Media 2015.
48. Gray PN et al. Not all next Generation sequencing diagnostics are created equal: understanding the nuances of solid tumor assay design for somatic mutation detection. Cancers 2015;7:1313–32.
49. Jordan EJ et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017;7(6):596–609.
50. Pao W and Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175–80.
51. Buffery D. Innovation tops current trends in the 2016 oncology drug pipeline. Am Health Drug Benefits 2016;9(4):233–38.
52. Chmielecki J et al. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. The Oncologist 2015;20:7–12.
53. Ross JS et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: an emerging opportunity for anti-HER2 targeted therapies. Cancer 2016;122(17):2654–62.
54. FoundationACT Specimen Guidelines.
55. FoundationOne®Heme Specimen Guidelines.
56. Foundation Medicine: Press Releases. Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration. Apr 2018. Available at: http://investors.foundationmedicine.com/news-releases/news-release-details/foundation-medicines-new-liquid-biopsy-assay-granted (accessed 06/08/18)
57. Clark TA, et al. J Mol Diagn 2018. doi: 10.1016/j.jmoldx.2018.05.004. [Epub ahead of print]